PolyNovo Limited (ASX:PNV)
Australia
· Delayed Price · Currency is AUD | Market Cap | 625.21M |
| Revenue (ttm) | 139.49M |
| Net Income (ttm) | 9.88M |
| Shares Out | 690.84M |
| EPS (ttm) | 0.01 |
| PE Ratio | 64.32 |
| Forward PE | 42.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,853,419 |
| Average Volume | 2,826,915 |
| Open | 0.895 |
| Previous Close | 0.905 |
| Day's Range | 0.875 - 0.910 |
| 52-Week Range | 0.870 - 1.715 |
| Beta | 1.48 |
| RSI | 36.06 |
| Earnings Date | Feb 20, 2026 |
About PolyNovo
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to tre... [Read more]
Financial Performance
In fiscal year 2025, PolyNovo's revenue was 128.70 million, an increase of 24.67% compared to the previous year's 103.23 million. Earnings were 13.21 million, an increase of 151.17%.
Financial StatementsNews
PolyNovo Limited (CALZF) Q2 2026 Earnings Call Transcript
PolyNovo Limited (CALZF) Q2 2026 Earnings Call Transcript
PolyNovo Limited (CALZF) Shareholder/Analyst Call Transcript
PolyNovo Limited (OTCPK:CALZF) Shareholder/Analyst Call October 27, 2025 10:00 PM EDT Company Participants Leon Hoare Robyn Elliott - Acting CEO & MD Bruce Peatey Jan-Marcel Gielen - CFO & Company Sec...